Magnis Energy Technologies Ltd

MNS

Magnis Energy Technologies Ltd. is engaged in the business of exploring, developing and mining natural flake graphite and manufacturing lithium-ion battey. The company is headquartered in Sydney, New South Wales and currently employs 7 full-time employees. The company went IPO on 2005-10-25. The firm supports and accelerates the adoption of electric vehicles and renewable energy storage critical for the green energy transition. The firm's subsidiary, Imperium3 New York, Inc (iM3NY), operates a Gigawatt scale Lithium-ion battery manufacturing project in Endicott, New York. The company also has a joint venture and lithium-ion research and development (R&D) technology partner, Charge CCCV LLC (C4V). iM3NY has commercialized C4Vs patented cathode chemistry to produce green credentialed lithium-ion battery cells for use in both electric vehicles and battery energy storage systems. The firm also has a 100% interest in the Nachu Project, which is a large-scale natural flake graphite project in Tanzania.

Actinogen Medical Limited

ACW

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.

Aft Pharmaceuticals Limited

AFP

AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. The firm develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories around the world. The firm's segments include New Zealand, Australia, Asia and Rest of World. The firm's product portfolio targets various therapeutic areas, such as pain, eyecare, vitamins, allergy, gastrointestinal, dermatology and hospital. Its products include Maxigesic, ParaOsteo, ZoRub OA/HP, Fenpaed, Combolieve Day/Night, Hylo, Novatears, CromoFresh, Opti-soothe Wipes/Mask, VitAPOS, Ferro-liquid, FerroTab, Ferro-F, Ferro-sachets, Lipo VitC, Lipo VitD, CalciTab, Loraclear, Histaclear, Fexaclear, Levoclear, Allersoothe, Lorapaed, Becloclear, Steroclear, Gastrosoothe/Forte, LaxTab, Micolette, Nausicalm, DiaRelieve, Crystaderm, Crystawash Hand Sanitizer, Crystasoothe, ZoRub anti-chafing, Decazol, MycoNail and others.

Althea Group Holdings Limited

AGH

Althea Group Holdings Ltd. is an investment company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2018-09-21. The firm services these sectors via two business units: Althea and Peak Processing Solutions. Althea is its pharmaceutical business that offers a range of cannabis-based medicines which are made available to patients via prescription. Althea offers a range of education, access, and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways. Peak Processing Solutions is its recreational cannabis business, which produces legal cannabis products purchased by adult consumers in retail stores. Peak Processing Solutions provides formulation and mass-manufacturing of recreational cannabis products, including beverages, concentrates, topicals and others. The firm operates in regulated and legal cannabis markets across Europe, North America, Australia, and Africa.

GGUS

GGUS.AX was created on 2015-08-17 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund provides investors with a simple way to obtain a cost-effective geared exposure to the returns of the U.S. sharemarket, hedged to Australian Dollars.